Commercial support:  This program is supported by independent educational grants from Regeneron Pharmaceuticals, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.

All Times Listed are for the Central Standard Time Zone

• 2.00 ACPE Pharmacy
  

  The Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This conference is approved for up to 2.00 credit by the Washington State Pharmacy Association.

  This activity is approved for up to 2.00 credit by the Washington State Pharmacy Association. Activity Type: Live| Start/End date: Tue, 06/24/2025 – 7:30pm-Tue, 06/24/2025 – 9:30pm The Washington State Pharmacy Association (WSPA) is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. NOTE FOR PHARMACISTS: It is the responsibility of the pharmacist or pharmacy technician to provide the correct information [NABP eProfile ID and DOB (in MMDD format)] within the evaluation, in order to receive credit for participating in this CPE activity. Following the activity’s end date, there is a maximum of 60 days allowed to upload the CPE information to the CPE Monitor. WSPA will upload the CPE information to the CPE monitor 50 days after the activity – please check your CPE Monitor at this time to ensure the CPE is uploaded in your profile. If you encounter any CPE problems, please contact WSPA at 425- 228-7171

• 2.00 AMA PRA Category 1 Credit™
  

  This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

  Horizon CME designates this Live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

• 2.00 ANCC
  
  This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 2.00 credit.
• 0.75 Pharmacology
  
  This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 0.75 credit.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Jesús G. Berdeja, M.D. discloses contracted research with 2 Seventy Bio, Abbvie, Amgen, BMS, C4 Therapeutics, Caribou Biosciences, CARsgen, Cartesian Therapeutics, Celularity, CRISPR Therapeutics, Fate Therapeutics, Genentech, GSK, Ichnos Sciences, Incyte, Janssen, Juno Therapeutics, K36 Therapeutics. Karyopharm, Lilly, Novartis, Poseida, Roche, Sanofi, Takeda, Consulting Fee’s with AstraZeneca, BMS, Caribou Biosciences, Galapagos, Janssen, K36 Therapeutics, Kite Pharma, Legend Biotech, Pfizer, Regeneron, Roche, Sanofi, Sebia, Takeda and Speaker’s Honoria with Janssen during the past 24 months. 

Muhamed Baljević, MD, FACP discloses that he is on an advisory board for BristolMyersSquibb, Johnson & Johnson, MM Prothena, Pfizer and Sanofi during the past 24 months.

Charise Gleason, MSN, NP-C, AOCNP discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.

Kathryn Kennedy, APRN discloses that she is a speaker for Geron as well as on advisory boards for CTI BIOp, Gero and Pfizer during the past 24 months.

Justin LaPorte, PharmD, BCOP discloses that he is a speaker for Johnson & Johnson and Syndax during the past 24 months.

Sarah Profitt, PharmD, BCOP discloses that she is on an advisory board for EIi Lilly & Company, Genentech Inc. and Rigel Pharmaceuticals during the past 24 months.